nach oben

Drugs

Erschienen in:

01.12.2007 | Review Article

Histamine and Leukotriene Receptor Antagonism in the Treatment of Allergic Rhinitis

An Update

verfasst von: Dr Helen Van Hoecke, Liesbet Vandenbulcke, Paul Van Cauwenberge

Erschienen in: Drugs | Ausgabe 18/2007

Einloggen, um Zugang zu erhalten

Abstract

Allergic rhinitis represents a global health burden. The disease can seriously affect quality of life and is associated with multiple co-morbidities. Histamine and leukotrienes are important pro-inflammatory mediators in nasal allergic inflammation. Their actions on target cells are mediated through specific receptors and, consequently, molecules that block the binding of histamine and leukotrienes to their receptors have been important areas of pharmacological research.

The published literature of the pathophysiology of histamine and leukotrienes, and the effects of histamine H₁-receptor antagonists (H₁ antihistamines) and leukotriene antagonists in monotherapy or in combination therapy in the treatment of allergic rhinitis was reviewed. The presented results are based on the best available evidence.

The efficacy of H₁ antihistamines and leukotriene antagonists (montelukast in particular) in allergic rhinitis has been established in numerous randomised placebo-controlled trials. Results from meta-analyses indicate that H₁ antihistamines and leukotriene antagonists are equally effective in improving symptoms of allergic rhinitis and quality of life, but that both drugs are less effective than intranasal corticosteroids.

Data on the combination of H₁ antihistamines and leukotriene antagonists in allergic rhinitis are limited. The available evidence shows that a combined mediator inhibition has additional benefits over the use of each agent alone, but is still inferior to intranasal corticosteroids. More well designed studies are needed to fully understand the benefits of a concomitant use of these agents.

Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113(5): 832–6PubMedCrossRef

Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 Suppl. 5: S147–334PubMedCrossRef

Spector SL. Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997; 99(2): S773–80PubMedCrossRef

Meltzer EO. An overview of current pharmacotherapy in perennial rhinitis. J Allergy Clin Immunol 1995; 95 (5 Pt 2): 1097–110PubMedCrossRef

Dale H, Laidlaw P. The physiological action of beta-imidazo-lethilamine. J Physiol (London) 1910; 41: 427–39

Ash AS, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol 1966; 27(2): 427–39

Taylor-Clark T, Foreman J. Histamine-mediated mechanisms in the human nasal airway. Curr Opin Pharmacol 2005; 5(3): 214–20PubMedCrossRef

Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313(2): 65–70PubMedCrossRef

Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351(21): 2203–17PubMedCrossRef

10.

Bachert C. Histamine: a major role in allergy? Clin Exp Allergy 1998; 28 Suppl. 6: 15–9PubMedCrossRef

11.

Jutel M, Akdis CA, Blaser K. Histamine in allergic inflammation and immune regulation. Int Arch Allergy Immunol 2005; 137(1): 82–92PubMedCrossRef

12.

Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002; 32(4): 489–98PubMedCrossRef

13.

Bachert C. The role of histamine in allergic disease: re-appraisal of its inflammatory potential. Allergy 2002; 57(4): 287–96PubMedCrossRef

14.

Camelo-Nunes IC. New antihistamines: a critical view. J Pediatr (Rio J) 2006; 82 (5 Suppl.): S173–80CrossRef

15.

Simons FE. H1-receptor antagonists: comparative tolerability and safety. Drug Saf 1994; 10(5): 350–80PubMedCrossRef

16.

Pfizer. Cetirizine [prescribing information]. New York, 1997

17.

McTavish D, Sorkin EM. Azelastine: a review of its pharmaco-dynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989; 38(5): 778–800PubMedCrossRef

18.

Passalacqua G, Canonica GW, Bousquet J. Structure and classification of H1-antihistamines and overview of their activities. Clin Allergy Immunol 2002; 17: 65–100PubMed

19.

Holgate ST, Canonica GW, Simons FE, et al. Consensus Group on New-Generation Antihistamines. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003; 33(9): 1305–24

20.

Conde Hernandez DJ, Palma Aqilar JL, Delgado Romero J. Comparison of azelastine nasal spray and oral ebastine in treatment of seasonal allergic rhinitis. Curr Med Res Opin 1995; 13(6): 299–304PubMedCrossRef

21.

Canonica GW, Ciprandi G, Petzold U, et al. Topical azelastine in perennial allergic conjunctivitis. Curr Med Res Opin 2003; 19(4): 321–9PubMedCrossRef

22.

Hore I, Georgalas C, Scadding G. Oral antihistamines for the symptom of nasal obstruction in persistent allergic rhinitis: a systematic review of randomized controlled trials. Clin Exp Allergy 2005; 35(2): 207–12PubMedCrossRef

23.

Stern MA, Wade AG, Ridout SM, et al. Nasal budesonide offers superior symptom relief in perennial allergic rhinitis in comparison to nasal azelastine. Ann Allergy Asthma Immunol 1998; 81(4): 354–8PubMedCrossRef

24.

Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317(7173): 1624–9PubMedCrossRef

25.

Schata M, Jorde W, Richarz-Barthauer U. Levocabastine nasal spray better than sodium cromoglycate and placebo in the topical treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1991; 87(4): 873–8PubMedCrossRef

26.

James IG, Campbell LM, Harrison JM, et al. Comparison of the efficacy and tolerability of topically administered azelastine, sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis and rhino-conjunctivitis. Curr Med Res Opin 2003; 19(4): 313–20PubMedCrossRef

27.

Wilson AM, O’Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004; 116(5): 338–44PubMedCrossRef

28.

Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104(5): 927–33PubMedCrossRef

29.

Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120mg, loratadine 10mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy 2000; 30(6): 891–9PubMedCrossRef

30.

Kaiser HB, Rooklin A, Spangler D, et al. Efficacy of loratadine compared with fexofenadine or placebo for the treatment of seasonal allergic rhinitis. Clin Drug Invest 2001; 21: 571–8CrossRef

31.

van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. EAACI Position paper. Allergy 2000; 55(2): 116–34

32.

Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A 1979; 76(9): 4275–9PubMedCrossRef

33.

Peters-Golden M, Gleason MM, Togias A. Cysteinyl leuko-trienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006 Jun; 36(6): 689–703PubMedCrossRef

34.

Currie GP, Srivastava P, Dempsey OJ, et al. Therapeutic modulation of allergic airways disease with leukotriene receptor antagonists. Q J Med 2005; 98(3): 171–82CrossRef

35.

Salvi SS, Krishna MT, Sampson AP, et al. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest 2001; 119(5): 1533–46PubMedCrossRef

36.

Knani J, Campbell A, Enander I, et al. Indirect evidence of nasal inflammation assessed by titration of inflammatory mediators and enumeration of cells in nasal secretions of patients with chronic rhinitis. J Allergy Clin Immunol 1992; 90: 880–9PubMedCrossRef

37.

Kojima T, Asakura K. A study of chemical mediators in patients with allergic rhinitis: 3. Release of histamine and leukotrienes from in vitro nasal mucosa. Nippon Jibiinkoka Gakkai Kaiho 1991; 94: 587–93

38.

Garrelds IM, Koenders S, de Graaf-in ’t Veld C, et al. Relationship between nasal hyperreactivity, mediators and eosinophils in patients with perennial allergic rhinitis and controls. Clin Exp Allergy 1996; 26: 903–8PubMedCrossRef

39.

Wang D, Clement P, Smitz J, et al. Correlations between complaints, inflammatory cells and mediator concentrations in nasal secretions after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995; 106: 278–85PubMedCrossRef

40.

Skoner DP, Lee L, Doyle WJ, et al. Nasal physiology and inflammatory mediators during natural pollen exposure. Ann Allergy 1990; 65: 206–10PubMed

41.

Peters-Golden M, Henderson Jr WR. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol 2005; 94(6): 609–18PubMedCrossRef

42.

Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis based on the concept of “one linked airway disease”. Ann allergy Asthma Immunol 2000; 84(2): 176–85PubMedCrossRef

43.

Mygind N, Dahl R, Bisgaard H. Leukotrienes, leukotriene receptor antagonists, and rhinitis. Allergy 2000 May; 55(5): 421–4PubMedCrossRef

44.

Ribeiro JD, Toro AA, Baracat EC. Antileukotrienes in the treatment of asthma and allergic rhinitis. J Pediatr (Rio J) 2006; 82 (5 Suppl.): S213–21CrossRef

45.

Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J Pediatr 2006; 73: 275–82PubMedCrossRef

46.

Chen ST, Lu KH, Sun HL, et al. Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2–6 yr. Pediatr Allergy Immunol 2006; 17: 49–54PubMedCrossRef

47.

Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol 2004; 92(3): 367–73PubMedCrossRef

48.

Nayak AS, Philip G, Lu S, et al. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88(6): 592–600PubMedCrossRef

49.

Patel P, Philip G, Yang W, et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol 2005; 95(6): 551–7PubMedCrossRef

50.

Rodrigo GJ, Yanez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol 2006; 96(6): 779–86PubMedCrossRef

51.

Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy 1997; 52 Suppl. 40: 12–8CrossRef

52.

Okuda M, Watase T, Mercuwa A, et al. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988; 60: 537–40PubMed

53.

Meltzer EO, Malmstrom K, Lu S, et al. Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: placebo-controlled clinical trial. J Allergy Clin Immunol 2000; 105(5): 917–22PubMedCrossRef

54.

Ciebiada M, Gorska-Ciebiada M, DuBuske LM, et al. Montelukast with desloratadine or levocetirizine for the treatment of persistent allergie rhinitis. Ann Allergy Asthma Immunol 2006; 97(5): 664–71PubMedCrossRef

55.

Kurowski M, Kuna P, Gorski P. Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004; 59(3): 280–8PubMedCrossRef

56.

Wilson AM, Sims EJ, Orr LC, et al. Effects of topical cortico-steroid and combined mediator blockade on domiciliary and laboratory measurements of nasal function in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2001; 87(4): 344–9PubMedCrossRef

57.

Wilson AM, Dempsey OJ, Sims EJ, et al. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001; 31(4): 616–24PubMedCrossRef

58.

Pullerits T, Praks L, Ristoja V, et al. Comparison of a nasal glucocorticosteroid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109(6): 949–55PubMedCrossRef

59.

Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004; 34(2): 259–67PubMedCrossRef

Titel: Histamine and Leukotriene Receptor Antagonism in the Treatment of Allergic Rhinitis
An Update
verfasst von: Dr Helen Van Hoecke
Liesbet Vandenbulcke
Paul Van Cauwenberge
Publikationsdatum: 01.12.2007
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 18/2007
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200767180-00006

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Histamine and Leukotriene Receptor Antagonism in the Treatment of Allergic Rhinitis

An Update

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 18/2007

Treatment of Lysosomal Storage Disorders

Trastuzumab

Darunavir in the Treatment of HIV-1 Infection

Darunavir

Darunavir in the Treatment of HIV-1 Infection

Guidelines for the Management of Lyme Disease